GlassScriptPhysician profile
Robert J Resnik
NPI 1346209400
$6,069.20
in general payments reported to CMS, 2019-2025
50 companies · $790 in 2025
The $790 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $1,025 · 2021: $1,006 · 2022: $651 · 2023: $916 · 2024: $819 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,445.05 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $799.20 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $708.60 | 2019-2025 | |
| Pfizer INC. | $525.20 | 2019-2025 | |
| Amgen INC. | $480.22 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $414.78 | 2023-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $383.61 | 2019-2022 | |
| Lilly USA, LLC | $380.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $350.11 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $332.12 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $187.12 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $99.85 | 2021-2022 | |
| Abbott Laboratories | $94.68 | 2021-2025 | Proclaim |
| Eisai INC. | $86.31 | 2020-2024 | |
| Amarin Pharma, INC. | $85.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.47 | 2020-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Resnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.